Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Net Income towards Common Stockholders came in at $118.4 million in Q1 2026, up 62.34% year-on-year from $72.9 million in Q1 2025, and up 118.93% on a QoQ basis from $54.1 million in Q4 2025.
Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Net Income towards Common Stockholders data on file, last reported at $118.4 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 62.34% year-over-year to $118.4 million in Q1 2026; TTM through Mar 2026 was $279.0 million, a 9.72% increase from a year earlier, with the FY2025 full-year figure at $233.6 million, down 25.25% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $118.4 million, up from $54.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for LNTH reached as high as $132.0 million in Q3 2023 and fell as low as -$119.2 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged $59.8 million across 5 years, with a median of $62.1 million in 2024.
- Across the five-year window, Net Income towards Common Stockholders slumped 196.37% in 2022 and surged 4769.26% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$119.2 million in 2022, then surged by 185.05% to $101.4 million in 2023, then sank by 111.63% to -$11.8 million in 2024, then soared by 558.76% to $54.1 million in 2025, then soared by 118.93% to $118.4 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 91.93 Bn | 90.07 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.31 Bn | 32.57 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 33.01 Bn | 31.07 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.96 Bn | 20.81 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.50 Bn | 18.69 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 18.16 Bn | 16.85 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.84 Bn | 12.41 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Lantheus Holdings | 6.58 Bn | 6.08 Bn | 230.92 Mn | 118.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 54.09 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -11.79 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |
| Jun 30, 2021 | -26.66 Mn |